Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Место комбинированных гормональных контрацептивов в терапии акне у женщин
Место комбинированных гормональных контрацептивов в терапии акне у женщин
Успенская Ю.Б. Место комбинированных гормональных контрацептивов в терапии акне у женщин. Consilium Medicum. 2020; 22 (7): 69–72.
DOI: 10.26442/20751753.2020.7.200308
DOI: 10.26442/20751753.2020.7.200308
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Гиперандрогения играет значимую роль в патогенезе акне. Андрогены способствуют гиперплазии сальных желез, повышенной продукции кожного сала и гиперкератозу. Избыточные влияния андрогенов на кожу обусловлены гиперандрогенией на фоне различных эндокринных синдромов или повышенной чувствительностью рецепторов кожи к нормальным концентрациям мужских половых гормонов и локальной гиперпродукцией андрогенов. Применение комбинированных оральных контрацептивов (КОК) имеет терапевтический потенциал при лечении акне у пациенток с гиперандрогенией и у женщин с нормальным уровнем андрогенов. Использование КОК может являться альтернативой системной терапии антибактериальными препаратами и ретиноидами. Решение вопроса о назначении КОК пациенткам с акне должно приниматься совместно, при участии дерматолога, гинеколога или эндокринолога.
Ключевые слова: угревая болезнь, гиперандрогения, андрогены, тестостерон, прогестины.
Key words: acne, hyperandrogenism, androgens, testosterone, progestins
Ключевые слова: угревая болезнь, гиперандрогения, андрогены, тестостерон, прогестины.
________________________________________________
Key words: acne, hyperandrogenism, androgens, testosterone, progestins
Полный текст
Список литературы
1. George R, Clarke S, Thiboutot D. Hormonal therapy for acne. Semin Cutan Med Surg 2008; 27: 188–96.
2. Горячкина М.В. Роль психоэмоциональных факторов в развитии акне. Дерматология (Прил. к журн. Consilium Medicum). 2008; 2: 8–12.
[Goriachkina M.V. Rol' psikhoemotsional'nykh faktorov v razvitii akne. Dermatology (Suppl. Consilium Medicum). 2008; 2: 8–12 (in Russian).]
3. Горячкина М.В. Комбинированная терапия акне у женщин: поиск оптимальных решений. Вестн. дерматологии и венерологии. 2014; 2: 90–5.
[Goriachkina M.V. Kombinirovannaia terapiia akne u zhenshchin: poisk optimal'nykh reshenii. Vestn. dermatologii i venerologii. 2014; 2: 90–5 (in Russian).]
4. O'Neill AM, Gallo RL. Host-microbiome interactions and recent progress into understanding the biology of acne vulgaris. Microbiome 2018; 6 (1): 177. DOI: 10.1186/s40168-018-0558-5
5. Gollnick H, Cunliffe W, Berson D et al. Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol 2003; 49 (Suppl. 1): S1–S37. DOI: 10.1067/mjd.2003.618
6. Горячкина М.В., Белоусова Т.А. Современные представления о патогенезе, клинике и терапии акне у женщин. Рус. мед. журн. 2012; 22: 1153–8.
[Goriachkina M.V., Belousova T.A. Sovremennye predstavleniia o patogeneze, klinike i terapii akne u zhenshchin. Rus. med. zhurn. 2012; 22: 1153–8 (in Russian).]
7. Доброхотова Ю.Э., Джобава Э.М., Рагимова З.Ю. и др. Синдром гиперандрогении в практике акушера-гинеколога, дерматолога, эндокринолога: руководство для врачей. М. : ГЭОТАР–Медиа, 2009.
[Dobrokhotova Iu.E., Dzhobava E.M., Ragimova Z.Iu. et al. Hyperandrogenic syndrome in the practice of obstetrician-gynecologist, dermatologist, endocrinologist: a guide for doctors. Moscow: GEOTAR–Media, 2009 (in Russian).]
8. Bansal P, Sardana K, Sharma L et al. A prospective study examining isolated acne and acne with hyperandrogenic signs in adult females. J Dermatolog Treat 2020; 1–4. DOI: 10.1080/09546634.2019.1708245
9. Zaenglein A, Pathy A, Schlosser B et al. Guidelines of care for the treatment of acne vulgaris. J Am Acad Dermatol 2016; 74 (5): 945–73.
10. Choudhry R, Hodgins MB, Van der Kwast TH et al. Localization of androgen receptors in human skin by immunohistochemistry: implications for the hormonal regulation of hair growth, sebaceous glands and sweat glands. J Endocrinol 1992; 133 (3): 467–75. DOI: 10.1677/joe.0.1330467
11. Thiboutot DM, Knaggs H, Gilliland K, Hagari S. Activity of type 1 5 alpha-reductase is greater in the follicular infrainfundibulum compared with the epidermis. Br J Dermatol 1997; 136 (2): 166–71
12. Arrington E, Patel N, Gerancher K et al. Combined oral contraceptives for the treatment of acne: a practical guide. Cutis 2012; 90 (2): 83–90.
13. Kurokawa I, Danby F, Ju Q, et al. New developments in our understanding of acne pathogenesis and treatment. Exp Dermatol 2009; 18: 821–32.
14. Arowojolu O, Gallo M, Lopez L et al. Combined oral contraceptive pills for treatment of acne. Cochrane Database Syst Rev 2012; 6: CD004425.
15. Katsambas AD, Dessinioti C. Hormonal therapy for acne: why not as first lineb therapy? facts and controversies. Clin Dermatol 2010; 28 (1): 17–23.
16. Lucky A, Koltun W, Thiboutot D et al. A combined oral contraceptive containing 3-mg drospirenone/20-microg ethinyl estradiol in the treatment of acne vulgaris: a randomized, double-blind, placebocontrolled study evaluating lesion counts and participant self-assessment. Cutis 2008; 82: 143–50.
17. Marson JW, Baldwin HE. An Overview of Acne Therapy, Part 2: Hormonal Therapy and Isotretinoin. Dermatol Clin 2019; 37 (2): 195–203. DOI: 10.1016/j.det.2018.12.002
18. Акне. Клинические рекомендации. 2016. Рубрикатор клинических рекомендаций Минздрава РФ. http://cr.rosminzdrav.ru/schema.html?id=721#/text
[Akne. Klinicheskie rekomendatsii. 2016. Rubrikator klinicheskikh rekomendatsii Minzdrava RF
(in Russian).]
19. Oon HH, Wong SN, Aw DCW et al. Acne Management Guidelines by the Dermatological Society
of Singapore. J Clin Aesthet Dermatol 2019; 12 (7): 34–50.
20. Bhate K, Williams HC. What’s new in acne? An analysis of systematic reviews published
in 2011–2012. Clin Exp Dermatol 2014; 39 (3): 273–8.
21. Koltun W, Lucky A, Thiboutot D et al. Efficacy and safety of 3 mg drospirenone/20 mcg ethinylestradiol oral contraceptive administered in 24/4 regimen in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled trial. Contraception 2008; 77: 249–56.
22. Maloney J, Dietze P, Watson D et al. A randomized controlled trial of a low-dose combined oral contraceptive containing 3 mg drospirenone plus 20 microg ethinylestradiol in the treatment of acne vulgaris: lesion counts, investigator ratings and subject self-assessment. J Drugs Dermatol 2009; 8: 837–44.
23. Maloney J, Dietze P, Watson D et al. Treatment of acne using a 3-milligram drospirenone/20- microgram ethinyl estradiol oral contraceptive administered in a 24/4 regimen: a randomized controlled trial. Obstet Gynecol 2008; 112: 773–81.
24. Plewig G, Cunliffe W, Binder N et al. Efficacy of an oral contraceptive containing EE 0.03 mg and CMA 2 mg (Belara) in moderate acne resolution: a randomized, double-blind, placebo-controlled phase III trial. Contraception 2009; 80: 25–33.
25. Nast A, Dréno B, Bettoli V et al. European evidence-based (S3) guideline for the treatment of acne – update 2016 – short version. J Eur Acad Dermatol Venereol 2016; 30 (8): 1261–8. DOI: 10.1111/jdv.13776
26. Rich P. Hormonal contraceptives for acne management. Cutis 2008; 81 (Suppl. 1): 13–8.
27. Zouboulis CC, Rabe T. Hormonal antiandrogens in acne treatment. J Dtsch Dermatol Ges 2010; 1 (Suppl. 8): S60–S74.
28. Koltun W, Maloney J, Marr J et al. Treatment of moderate acne vulgaris using a combined oral contraceptive containing ethinylestradiol 20 mg plus drospirenone 3 mg administered in a 24/4 regimen: a pooled analysis. Eur J Obstet Gynecol Reprod Biol 2011; 155: 171–5.
29. Beral V, Hermon C, Kay C et al. Mortality associated with oral contraceptive use: 25 year follow up of cohort of 46,000 women from Royal College of General Practitioners: oral contraception study. BMJ 1999; 318: 96–100.
30. Kim G, Michaels B. Post-adolescent acne in women: more common and more clinical considerations. J Drugs Dermatol 2012; 11: 708–13.
31. Rott H. Thrombotic risks of oral contraceptives. Curr Opin Obstet Gynecol 2012; 24: 235–40.
32. Lidegaard O, Edstrom B, Keriner S. Oral contraceptives and venous thromboembolism: a five-year national case-control study. Contraception 2002; 65: 187–96.
33. Lam C, Zaenglein A. Contraceptive use in acne. Clin Dermatol 2014; 32 (4): 502–15.
34. Drife J. The contraceptive pill and breast cancer in young women. BMJ 1989; 298: 1269–70.
35. Sasieni P. Cervical cancer prevention and hormonal contraception. Lancet 2007; 370: 1591–2.
36. Simmons KB, Haddad LB, Nanda K, Curtis KM. Drug interactions between non-rifamycin antibiotics and hormonal contraception: a systematic review. Am J Obstet Gynecol 2018; 218 (1): 88–97.e14. DOI: 10.1016/j.ajog.2017.07.003
37. Weaver K, Glasier A. Interaction between broad-spectrum antibiotics and the combined oral contraceptive pill. A literature review. Contraception 1999; 59 (2): 71–8. DOI: 10.1016/s0010-7824(99)00009-8
2. Goriachkina M.V. Rol' psikhoemotsional'nykh faktorov v razvitii akne. Dermatology (Suppl. Consilium Medicum). 2008; 2: 8–12 (in Russian).
3. Goriachkina M.V. Kombinirovannaia terapiia akne u zhenshchin: poisk optimal'nykh reshenii. Vestn. dermatologii i venerologii. 2014; 2: 90–5 (in Russian).
4. O'Neill AM, Gallo RL. Host-microbiome interactions and recent progress into understanding the biology of acne vulgaris. Microbiome 2018; 6 (1): 177. DOI: 10.1186/s40168-018-0558-5
5. Gollnick H, Cunliffe W, Berson D et al. Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol 2003; 49 (Suppl. 1): S1–S37. DOI: 10.1067/mjd.2003.618
6. Goriachkina M.V., Belousova T.A. Sovremennye predstavleniia o patogeneze, klinike i terapii akne u zhenshchin. Rus. med. zhurn. 2012; 22: 1153–8 (in Russian).
7. Dobrokhotova Iu.E., Dzhobava E.M., Ragimova Z.Iu. et al. Hyperandrogenic syndrome in the practice of obstetrician-gynecologist, dermatologist, endocrinologist: a guide for doctors. Moscow: GEOTAR–Media, 2009 (in Russian).
8. Bansal P, Sardana K, Sharma L et al. A prospective study examining isolated acne and acne with hyperandrogenic signs in adult females. J Dermatolog Treat 2020; 1–4. DOI: 10.1080/09546634.2019.1708245
9. Zaenglein A, Pathy A, Schlosser B et al. Guidelines of care for the treatment of acne vulgaris. J Am Acad Dermatol 2016; 74 (5): 945–73.
10. Choudhry R, Hodgins MB, Van der Kwast TH et al. Localization of androgen receptors in human skin by immunohistochemistry: implications for the hormonal regulation of hair growth, sebaceous glands and sweat glands. J Endocrinol 1992; 133 (3): 467–75. DOI: 10.1677/joe.0.1330467
11. Thiboutot DM, Knaggs H, Gilliland K, Hagari S. Activity of type 1 5 alpha-reductase is greater in the follicular infrainfundibulum compared with the epidermis. Br J Dermatol 1997; 136 (2): 166–71
12. Arrington E, Patel N, Gerancher K et al. Combined oral contraceptives for the treatment of acne: a practical guide. Cutis 2012; 90 (2): 83–90.
13. Kurokawa I, Danby F, Ju Q, et al. New developments in our understanding of acne pathogenesis and treatment. Exp Dermatol 2009; 18: 821–32.
14. Arowojolu O, Gallo M, Lopez L et al. Combined oral contraceptive pills for treatment of acne. Cochrane Database Syst Rev 2012; 6: CD004425.
15. Katsambas AD, Dessinioti C. Hormonal therapy for acne: why not as first lineb therapy? facts and controversies. Clin Dermatol 2010; 28 (1): 17–23.
16. Lucky A, Koltun W, Thiboutot D et al. A combined oral contraceptive containing 3-mg drospirenone/20-microg ethinyl estradiol in the treatment of acne vulgaris: a randomized, double-blind, placebocontrolled study evaluating lesion counts and participant self-assessment. Cutis 2008; 82: 143–50.
17. Marson JW, Baldwin HE. An Overview of Acne Therapy, Part 2: Hormonal Therapy and Isotretinoin. Dermatol Clin 2019; 37 (2): 195–203. DOI: 10.1016/j.det.2018.12.002
18. Akne. Klinicheskie rekomendatsii. 2016. Rubrikator klinicheskikh rekomendatsii Minzdrava RF(in Russian).
19. Oon HH, Wong SN, Aw DCW et al. Acne Management Guidelines by the Dermatological Society
of Singapore. J Clin Aesthet Dermatol 2019; 12 (7): 34–50.
20. Bhate K, Williams HC. What’s new in acne? An analysis of systematic reviews published
in 2011–2012. Clin Exp Dermatol 2014; 39 (3): 273–8.
21. Koltun W, Lucky A, Thiboutot D et al. Efficacy and safety of 3 mg drospirenone/20 mcg ethinylestradiol oral contraceptive administered in 24/4 regimen in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled trial. Contraception 2008; 77: 249–56.
22. Maloney J, Dietze P, Watson D et al. A randomized controlled trial of a low-dose combined oral contraceptive containing 3 mg drospirenone plus 20 microg ethinylestradiol in the treatment of acne vulgaris: lesion counts, investigator ratings and subject self-assessment. J Drugs Dermatol 2009; 8: 837–44.
23. Maloney J, Dietze P, Watson D et al. Treatment of acne using a 3-milligram drospirenone/20- microgram ethinyl estradiol oral contraceptive administered in a 24/4 regimen: a randomized controlled trial. Obstet Gynecol 2008; 112: 773–81.
24. Plewig G, Cunliffe W, Binder N et al. Efficacy of an oral contraceptive containing EE 0.03 mg and CMA 2 mg (Belara) in moderate acne resolution: a randomized, double-blind, placebo-controlled phase III trial. Contraception 2009; 80: 25–33.
25. Nast A, Dréno B, Bettoli V et al. European evidence-based (S3) guideline for the treatment of acne – update 2016 – short version. J Eur Acad Dermatol Venereol 2016; 30 (8): 1261–8. DOI: 10.1111/jdv.13776
26. Rich P. Hormonal contraceptives for acne management. Cutis 2008; 81 (Suppl. 1): 13–8.
27. Zouboulis CC, Rabe T. Hormonal antiandrogens in acne treatment. J Dtsch Dermatol Ges 2010; 1 (Suppl. 8): S60–S74.
28. Koltun W, Maloney J, Marr J et al. Treatment of moderate acne vulgaris using a combined oral contraceptive containing ethinylestradiol 20 mg plus drospirenone 3 mg administered in a 24/4 regimen: a pooled analysis. Eur J Obstet Gynecol Reprod Biol 2011; 155: 171–5.
29. Beral V, Hermon C, Kay C et al. Mortality associated with oral contraceptive use: 25 year follow up of cohort of 46,000 women from Royal College of General Practitioners: oral contraception study. BMJ 1999; 318: 96–100.
30. Kim G, Michaels B. Post-adolescent acne in women: more common and more clinical considerations. J Drugs Dermatol 2012; 11: 708–13.
31. Rott H. Thrombotic risks of oral contraceptives. Curr Opin Obstet Gynecol 2012; 24: 235–40.
32. Lidegaard O, Edstrom B, Keriner S. Oral contraceptives and venous thromboembolism: a five-year national case-control study. Contraception 2002; 65: 187–96.
33. Lam C, Zaenglein A. Contraceptive use in acne. Clin Dermatol 2014; 32 (4): 502–15.
34. Drife J. The contraceptive pill and breast cancer in young women. BMJ 1989; 298: 1269–70.
35. Sasieni P. Cervical cancer prevention and hormonal contraception. Lancet 2007; 370: 1591–2.
36. Simmons KB, Haddad LB, Nanda K, Curtis KM. Drug interactions between non-rifamycin antibiotics and hormonal contraception: a systematic review. Am J Obstet Gynecol 2018; 218 (1): 88–97.e14. DOI: 10.1016/j.ajog.2017.07.003
37. Weaver K, Glasier A. Interaction between broad-spectrum antibiotics and the combined oral contraceptive pill. A literature review. Contraception 1999; 59 (2): 71–8. DOI: 10.1016/s0010-7824(99)00009-8
2. Горячкина М.В. Роль психоэмоциональных факторов в развитии акне. Дерматология (Прил. к журн. Consilium Medicum). 2008; 2: 8–12.
[Goriachkina M.V. Rol' psikhoemotsional'nykh faktorov v razvitii akne. Dermatology (Suppl. Consilium Medicum). 2008; 2: 8–12 (in Russian).]
3. Горячкина М.В. Комбинированная терапия акне у женщин: поиск оптимальных решений. Вестн. дерматологии и венерологии. 2014; 2: 90–5.
[Goriachkina M.V. Kombinirovannaia terapiia akne u zhenshchin: poisk optimal'nykh reshenii. Vestn. dermatologii i venerologii. 2014; 2: 90–5 (in Russian).]
4. O'Neill AM, Gallo RL. Host-microbiome interactions and recent progress into understanding the biology of acne vulgaris. Microbiome 2018; 6 (1): 177. DOI: 10.1186/s40168-018-0558-5
5. Gollnick H, Cunliffe W, Berson D et al. Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol 2003; 49 (Suppl. 1): S1–S37. DOI: 10.1067/mjd.2003.618
6. Горячкина М.В., Белоусова Т.А. Современные представления о патогенезе, клинике и терапии акне у женщин. Рус. мед. журн. 2012; 22: 1153–8.
[Goriachkina M.V., Belousova T.A. Sovremennye predstavleniia o patogeneze, klinike i terapii akne u zhenshchin. Rus. med. zhurn. 2012; 22: 1153–8 (in Russian).]
7. Доброхотова Ю.Э., Джобава Э.М., Рагимова З.Ю. и др. Синдром гиперандрогении в практике акушера-гинеколога, дерматолога, эндокринолога: руководство для врачей. М. : ГЭОТАР–Медиа, 2009.
[Dobrokhotova Iu.E., Dzhobava E.M., Ragimova Z.Iu. et al. Hyperandrogenic syndrome in the practice of obstetrician-gynecologist, dermatologist, endocrinologist: a guide for doctors. Moscow: GEOTAR–Media, 2009 (in Russian).]
8. Bansal P, Sardana K, Sharma L et al. A prospective study examining isolated acne and acne with hyperandrogenic signs in adult females. J Dermatolog Treat 2020; 1–4. DOI: 10.1080/09546634.2019.1708245
9. Zaenglein A, Pathy A, Schlosser B et al. Guidelines of care for the treatment of acne vulgaris. J Am Acad Dermatol 2016; 74 (5): 945–73.
10. Choudhry R, Hodgins MB, Van der Kwast TH et al. Localization of androgen receptors in human skin by immunohistochemistry: implications for the hormonal regulation of hair growth, sebaceous glands and sweat glands. J Endocrinol 1992; 133 (3): 467–75. DOI: 10.1677/joe.0.1330467
11. Thiboutot DM, Knaggs H, Gilliland K, Hagari S. Activity of type 1 5 alpha-reductase is greater in the follicular infrainfundibulum compared with the epidermis. Br J Dermatol 1997; 136 (2): 166–71
12. Arrington E, Patel N, Gerancher K et al. Combined oral contraceptives for the treatment of acne: a practical guide. Cutis 2012; 90 (2): 83–90.
13. Kurokawa I, Danby F, Ju Q, et al. New developments in our understanding of acne pathogenesis and treatment. Exp Dermatol 2009; 18: 821–32.
14. Arowojolu O, Gallo M, Lopez L et al. Combined oral contraceptive pills for treatment of acne. Cochrane Database Syst Rev 2012; 6: CD004425.
15. Katsambas AD, Dessinioti C. Hormonal therapy for acne: why not as first lineb therapy? facts and controversies. Clin Dermatol 2010; 28 (1): 17–23.
16. Lucky A, Koltun W, Thiboutot D et al. A combined oral contraceptive containing 3-mg drospirenone/20-microg ethinyl estradiol in the treatment of acne vulgaris: a randomized, double-blind, placebocontrolled study evaluating lesion counts and participant self-assessment. Cutis 2008; 82: 143–50.
17. Marson JW, Baldwin HE. An Overview of Acne Therapy, Part 2: Hormonal Therapy and Isotretinoin. Dermatol Clin 2019; 37 (2): 195–203. DOI: 10.1016/j.det.2018.12.002
18. Акне. Клинические рекомендации. 2016. Рубрикатор клинических рекомендаций Минздрава РФ. http://cr.rosminzdrav.ru/schema.html?id=721#/text
[Akne. Klinicheskie rekomendatsii. 2016. Rubrikator klinicheskikh rekomendatsii Minzdrava RF
(in Russian).]
19. Oon HH, Wong SN, Aw DCW et al. Acne Management Guidelines by the Dermatological Society
of Singapore. J Clin Aesthet Dermatol 2019; 12 (7): 34–50.
20. Bhate K, Williams HC. What’s new in acne? An analysis of systematic reviews published
in 2011–2012. Clin Exp Dermatol 2014; 39 (3): 273–8.
21. Koltun W, Lucky A, Thiboutot D et al. Efficacy and safety of 3 mg drospirenone/20 mcg ethinylestradiol oral contraceptive administered in 24/4 regimen in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled trial. Contraception 2008; 77: 249–56.
22. Maloney J, Dietze P, Watson D et al. A randomized controlled trial of a low-dose combined oral contraceptive containing 3 mg drospirenone plus 20 microg ethinylestradiol in the treatment of acne vulgaris: lesion counts, investigator ratings and subject self-assessment. J Drugs Dermatol 2009; 8: 837–44.
23. Maloney J, Dietze P, Watson D et al. Treatment of acne using a 3-milligram drospirenone/20- microgram ethinyl estradiol oral contraceptive administered in a 24/4 regimen: a randomized controlled trial. Obstet Gynecol 2008; 112: 773–81.
24. Plewig G, Cunliffe W, Binder N et al. Efficacy of an oral contraceptive containing EE 0.03 mg and CMA 2 mg (Belara) in moderate acne resolution: a randomized, double-blind, placebo-controlled phase III trial. Contraception 2009; 80: 25–33.
25. Nast A, Dréno B, Bettoli V et al. European evidence-based (S3) guideline for the treatment of acne – update 2016 – short version. J Eur Acad Dermatol Venereol 2016; 30 (8): 1261–8. DOI: 10.1111/jdv.13776
26. Rich P. Hormonal contraceptives for acne management. Cutis 2008; 81 (Suppl. 1): 13–8.
27. Zouboulis CC, Rabe T. Hormonal antiandrogens in acne treatment. J Dtsch Dermatol Ges 2010; 1 (Suppl. 8): S60–S74.
28. Koltun W, Maloney J, Marr J et al. Treatment of moderate acne vulgaris using a combined oral contraceptive containing ethinylestradiol 20 mg plus drospirenone 3 mg administered in a 24/4 regimen: a pooled analysis. Eur J Obstet Gynecol Reprod Biol 2011; 155: 171–5.
29. Beral V, Hermon C, Kay C et al. Mortality associated with oral contraceptive use: 25 year follow up of cohort of 46,000 women from Royal College of General Practitioners: oral contraception study. BMJ 1999; 318: 96–100.
30. Kim G, Michaels B. Post-adolescent acne in women: more common and more clinical considerations. J Drugs Dermatol 2012; 11: 708–13.
31. Rott H. Thrombotic risks of oral contraceptives. Curr Opin Obstet Gynecol 2012; 24: 235–40.
32. Lidegaard O, Edstrom B, Keriner S. Oral contraceptives and venous thromboembolism: a five-year national case-control study. Contraception 2002; 65: 187–96.
33. Lam C, Zaenglein A. Contraceptive use in acne. Clin Dermatol 2014; 32 (4): 502–15.
34. Drife J. The contraceptive pill and breast cancer in young women. BMJ 1989; 298: 1269–70.
35. Sasieni P. Cervical cancer prevention and hormonal contraception. Lancet 2007; 370: 1591–2.
36. Simmons KB, Haddad LB, Nanda K, Curtis KM. Drug interactions between non-rifamycin antibiotics and hormonal contraception: a systematic review. Am J Obstet Gynecol 2018; 218 (1): 88–97.e14. DOI: 10.1016/j.ajog.2017.07.003
37. Weaver K, Glasier A. Interaction between broad-spectrum antibiotics and the combined oral contraceptive pill. A literature review. Contraception 1999; 59 (2): 71–8. DOI: 10.1016/s0010-7824(99)00009-8
________________________________________________
2. Goriachkina M.V. Rol' psikhoemotsional'nykh faktorov v razvitii akne. Dermatology (Suppl. Consilium Medicum). 2008; 2: 8–12 (in Russian).
3. Goriachkina M.V. Kombinirovannaia terapiia akne u zhenshchin: poisk optimal'nykh reshenii. Vestn. dermatologii i venerologii. 2014; 2: 90–5 (in Russian).
4. O'Neill AM, Gallo RL. Host-microbiome interactions and recent progress into understanding the biology of acne vulgaris. Microbiome 2018; 6 (1): 177. DOI: 10.1186/s40168-018-0558-5
5. Gollnick H, Cunliffe W, Berson D et al. Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol 2003; 49 (Suppl. 1): S1–S37. DOI: 10.1067/mjd.2003.618
6. Goriachkina M.V., Belousova T.A. Sovremennye predstavleniia o patogeneze, klinike i terapii akne u zhenshchin. Rus. med. zhurn. 2012; 22: 1153–8 (in Russian).
7. Dobrokhotova Iu.E., Dzhobava E.M., Ragimova Z.Iu. et al. Hyperandrogenic syndrome in the practice of obstetrician-gynecologist, dermatologist, endocrinologist: a guide for doctors. Moscow: GEOTAR–Media, 2009 (in Russian).
8. Bansal P, Sardana K, Sharma L et al. A prospective study examining isolated acne and acne with hyperandrogenic signs in adult females. J Dermatolog Treat 2020; 1–4. DOI: 10.1080/09546634.2019.1708245
9. Zaenglein A, Pathy A, Schlosser B et al. Guidelines of care for the treatment of acne vulgaris. J Am Acad Dermatol 2016; 74 (5): 945–73.
10. Choudhry R, Hodgins MB, Van der Kwast TH et al. Localization of androgen receptors in human skin by immunohistochemistry: implications for the hormonal regulation of hair growth, sebaceous glands and sweat glands. J Endocrinol 1992; 133 (3): 467–75. DOI: 10.1677/joe.0.1330467
11. Thiboutot DM, Knaggs H, Gilliland K, Hagari S. Activity of type 1 5 alpha-reductase is greater in the follicular infrainfundibulum compared with the epidermis. Br J Dermatol 1997; 136 (2): 166–71
12. Arrington E, Patel N, Gerancher K et al. Combined oral contraceptives for the treatment of acne: a practical guide. Cutis 2012; 90 (2): 83–90.
13. Kurokawa I, Danby F, Ju Q, et al. New developments in our understanding of acne pathogenesis and treatment. Exp Dermatol 2009; 18: 821–32.
14. Arowojolu O, Gallo M, Lopez L et al. Combined oral contraceptive pills for treatment of acne. Cochrane Database Syst Rev 2012; 6: CD004425.
15. Katsambas AD, Dessinioti C. Hormonal therapy for acne: why not as first lineb therapy? facts and controversies. Clin Dermatol 2010; 28 (1): 17–23.
16. Lucky A, Koltun W, Thiboutot D et al. A combined oral contraceptive containing 3-mg drospirenone/20-microg ethinyl estradiol in the treatment of acne vulgaris: a randomized, double-blind, placebocontrolled study evaluating lesion counts and participant self-assessment. Cutis 2008; 82: 143–50.
17. Marson JW, Baldwin HE. An Overview of Acne Therapy, Part 2: Hormonal Therapy and Isotretinoin. Dermatol Clin 2019; 37 (2): 195–203. DOI: 10.1016/j.det.2018.12.002
18. Akne. Klinicheskie rekomendatsii. 2016. Rubrikator klinicheskikh rekomendatsii Minzdrava RF(in Russian).
19. Oon HH, Wong SN, Aw DCW et al. Acne Management Guidelines by the Dermatological Society
of Singapore. J Clin Aesthet Dermatol 2019; 12 (7): 34–50.
20. Bhate K, Williams HC. What’s new in acne? An analysis of systematic reviews published
in 2011–2012. Clin Exp Dermatol 2014; 39 (3): 273–8.
21. Koltun W, Lucky A, Thiboutot D et al. Efficacy and safety of 3 mg drospirenone/20 mcg ethinylestradiol oral contraceptive administered in 24/4 regimen in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled trial. Contraception 2008; 77: 249–56.
22. Maloney J, Dietze P, Watson D et al. A randomized controlled trial of a low-dose combined oral contraceptive containing 3 mg drospirenone plus 20 microg ethinylestradiol in the treatment of acne vulgaris: lesion counts, investigator ratings and subject self-assessment. J Drugs Dermatol 2009; 8: 837–44.
23. Maloney J, Dietze P, Watson D et al. Treatment of acne using a 3-milligram drospirenone/20- microgram ethinyl estradiol oral contraceptive administered in a 24/4 regimen: a randomized controlled trial. Obstet Gynecol 2008; 112: 773–81.
24. Plewig G, Cunliffe W, Binder N et al. Efficacy of an oral contraceptive containing EE 0.03 mg and CMA 2 mg (Belara) in moderate acne resolution: a randomized, double-blind, placebo-controlled phase III trial. Contraception 2009; 80: 25–33.
25. Nast A, Dréno B, Bettoli V et al. European evidence-based (S3) guideline for the treatment of acne – update 2016 – short version. J Eur Acad Dermatol Venereol 2016; 30 (8): 1261–8. DOI: 10.1111/jdv.13776
26. Rich P. Hormonal contraceptives for acne management. Cutis 2008; 81 (Suppl. 1): 13–8.
27. Zouboulis CC, Rabe T. Hormonal antiandrogens in acne treatment. J Dtsch Dermatol Ges 2010; 1 (Suppl. 8): S60–S74.
28. Koltun W, Maloney J, Marr J et al. Treatment of moderate acne vulgaris using a combined oral contraceptive containing ethinylestradiol 20 mg plus drospirenone 3 mg administered in a 24/4 regimen: a pooled analysis. Eur J Obstet Gynecol Reprod Biol 2011; 155: 171–5.
29. Beral V, Hermon C, Kay C et al. Mortality associated with oral contraceptive use: 25 year follow up of cohort of 46,000 women from Royal College of General Practitioners: oral contraception study. BMJ 1999; 318: 96–100.
30. Kim G, Michaels B. Post-adolescent acne in women: more common and more clinical considerations. J Drugs Dermatol 2012; 11: 708–13.
31. Rott H. Thrombotic risks of oral contraceptives. Curr Opin Obstet Gynecol 2012; 24: 235–40.
32. Lidegaard O, Edstrom B, Keriner S. Oral contraceptives and venous thromboembolism: a five-year national case-control study. Contraception 2002; 65: 187–96.
33. Lam C, Zaenglein A. Contraceptive use in acne. Clin Dermatol 2014; 32 (4): 502–15.
34. Drife J. The contraceptive pill and breast cancer in young women. BMJ 1989; 298: 1269–70.
35. Sasieni P. Cervical cancer prevention and hormonal contraception. Lancet 2007; 370: 1591–2.
36. Simmons KB, Haddad LB, Nanda K, Curtis KM. Drug interactions between non-rifamycin antibiotics and hormonal contraception: a systematic review. Am J Obstet Gynecol 2018; 218 (1): 88–97.e14. DOI: 10.1016/j.ajog.2017.07.003
37. Weaver K, Glasier A. Interaction between broad-spectrum antibiotics and the combined oral contraceptive pill. A literature review. Contraception 1999; 59 (2): 71–8. DOI: 10.1016/s0010-7824(99)00009-8
Авторы
Ю.Б. Успенская*
ООО «Медицинский центр НЕБОЛИТ», Москва, Россия
*jusp@mail.ru
Medical Center NEBOLIT, Moscow, Russia
*jusp@mail.ru
ООО «Медицинский центр НЕБОЛИТ», Москва, Россия
*jusp@mail.ru
________________________________________________
Medical Center NEBOLIT, Moscow, Russia
*jusp@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.